Literature DB >> 21376284

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

Matthew D Galsky1, Noah M Hahn, Jonathan Rosenberg, Guru Sonpavde, Thomas Hutson, William K Oh, Robert Dreicer, Nicholas Vogelzang, Cora Sternberg, Dean F Bajorin, Joaquim Bellmunt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21376284     DOI： 10.1016/S1470-2045(10)70275-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  72 in total

Review 1.  Muscle-invasive urothelial bladder cancer: an update on systemic therapy.

Authors:  Hayley Knollman; J Luke Godwin; Rishi Jain; Yu-Ning Wong; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Ther Adv Urol       Date:  2015-12

2.  The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancer.

Authors:  Thomas Horn; Barbara Ladwein; Tobias Maurer; Jutta Redlin; Anna Katharina Seitz; Jürgen E Gschwend; Margitta Retz; Hubert R Kübler
Journal:  World J Urol       Date:  2013-05-26       Impact factor: 4.226

Review 3.  Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.

Authors:  Abhishek Tripathi; Elizabeth R Plimack
Journal:  Curr Urol Rep       Date:  2018-11-07       Impact factor: 3.092

4.  Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.

Authors:  J Martínez-Trufero; A Lozano Borbalas; I Pajares Bernad; M Taberna Sanz; E Ortega Izquierdo; B Cirauqui Cirauqui; J Rubió-Casadevall; M Plana Serrahima; J M Ponce Ortega; I Planas Toledano; J Caballero; J Marruecos Querol; L Iglesias Docampo; J Lambea Sorrosal; J C Adansa; R Mesía Nin
Journal:  Clin Transl Oncol       Date:  2021-04-19       Impact factor: 3.405

Review 5.  Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Authors:  David J Einstein; Guru Sonpavde
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

Review 6.  Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing.

Authors:  Morgan A Casal; Thomas D Nolin; Jan H Beumer
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-19       Impact factor: 8.237

7.  Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Underused across the 49th parallel.

Authors:  Michael J Raphael; Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2019-02       Impact factor: 1.862

8.  Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.

Authors:  Mark Warren; Michael Kolinsky; Christina M Canil; Piotr Czaykowski; Srikala S Sridhar; Peter C Black; Christopher M Booth; Wassim Kassouf; Libni Eapen; Som D Mukherjee; Normand Blais; Bernhard J Eigl; Eric Winquist; Naveen S Basappa; Scott A North
Journal:  Can Urol Assoc J       Date:  2019-04-26       Impact factor: 1.862

9.  Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer.

Authors:  Ajjai Alva; Terence Friedlander; Melanie Clark; Tamara Huebner; Stephanie Daignault; Maha Hussain; Cheryl Lee; Khaled Hafez; Brent Hollenbeck; Alon Weizer; Gayatri Premasekharan; Tony Tran; Christine Fu; Cristian Ionescu-Zanetti; Michael Schwartz; Andrea Fan; Pamela Paris
Journal:  J Urol       Date:  2015-04-23       Impact factor: 7.450

10.  Immune checkpoint inhibition in upper tract urothelial carcinoma.

Authors:  Gianluigi Califano; Idir Ouzaid; Paolo Verze; Jean-Francois Hermieu; Vincenzo Mirone; Evanguelos Xylinas
Journal:  World J Urol       Date:  2020-10-31       Impact factor: 4.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.